Senhwa Biosciences (生華生物科技股) is a drug development company focused on next-generation DNA damage response therapeutics for the treatment of cancer. It offers CX-5461, a G-quadruplexes stabilizer causing DNA damage of tumor cells through a synthetic lethality approach, and CX-4945, a protein kinase that elevates activity in many cancers and has a direct role in DNA damage repair.